Curing Broken Hearts

Even after a successful coronary angioplasty, one in three severe heart attack patients has impaired blood flow in the heart tissue.

PICSO® is designed to help these patients.

Miracor Medical Systems GmbH is commercializing a breakthrough technology, PICSO®, for improving outcomes for severe heart attack patients. The Miracor PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System seeks to improve blood flow in the heart tissue, thereby improving the overall heart function after a severe heart attack. More than 3 million patients are treated for restricted coronary blood flow every year. Of these more than 350,000 patients have poor heart tissue blood flow (microcirculation) even after successful balloon angioplasty or stent placement. Miracor is dedicated to help these patients to a better recovery after the heart attack.

The Miracor PICSO® Impulse System has received CE-mark and can be used during balloon angioplasty, stent placement or other methods for improving coronary blood flow. The Miracor PICSO® approach intermittently increases pressure in the coronary venous system, thereby redistributing blood flow into the affected heart tissue and, in some patients, also increases the coronary artery perfusion pressure during the PICSO® procedure.

On our Web pages you will learn more about Miracor, PICSO® and the future applications in interventional cardiology. Please contact us directly to receive additional information.

CE 0470

Red Herring Top 100

bio investor conference 2013 - top 35 innovation companies



Miracor Medical Systems to release latest clinical data using its PICSO® Impulse System


Miracor discloses strong trend toward a larger infarct size-reduction

receive news alerts

tl tr bl br PICSO®